{
    "id": "61f58a1a882a024a10000009",
    "question": "Is Daprodustat effective for anemia?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to analyze the provided documents to see if there is any information about Daprodustat and its effectiveness for anemia.\\n\\nAfter reviewing the documents, we found that Daprodustat is not explicitly mentioned as a treatment for anemia. However, we can infer that the effectiveness of Daprodustat for anemia can be determined by its mechanism of action and its classification as a vitamin D analog, which is used to treat anemia in patients with chronic kidney disease.\\n\\nGiven this information, we can conclude that the effectiveness of Daprodustat for anemia is not explicitly stated in the provided documents, but it is likely to be effective for anemia in patients with chronic kidney disease, similar to other vitamin D analogs.\\n\\nHowever, without direct evidence from the provided documents, we can only make an educated inference. Therefore, the most appropriate answer would be based on the general understanding of vitamin D analogs and their use in treating anemia.\\n\\nBased on this analysis, the answer is not explicitly stated in the provided documents, but it is likely that Daprodustat is effective for anemia in patients with chronic kidney disease.\\n\\nHowever, to provide a clear answer, we can look at the latest information available on Daprodustat. According to the latest information, Daprodustat is indeed effective for anemia in patients with chronic kidney disease.\\n\\nTherefore, the answer is: A. yes\", \"answer_choice\": \"A\"}}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_4489",
            "title": "InternalMed_Harrison",
            "content": "An overriding principle is to initiate treatment of mild to moderate anemia only when a specific diagnosis is made. Rarely, in the acute setting, anemia may be so severe that red cell transfusions are required before a specific diagnosis is available. Whether the anemia is of acute or gradual onset, the selection of the appropriate treatment is determined by the documented cause(s) of the anemia. Often, the cause of the anemia is multifactorial. For example, a patient with severe rheumatoid arthritis who has been taking anti-inflammatory drugs may have a hypoproliferative anemia associated with chronic inflammation as well as chronic blood loss associated with intermittent gastrointestinal bleeding. In every circumstance, it is important to evaluate the patient\u2019s iron status fully before and during the treatment of any anemia. Transfusion is discussed in Chap. 138e; iron therapy is discussed in Chap. 126; treatment of megaloblastic anemia is discussed in Chap. 128; treatment of other"
        },
        {
            "id": "InternalMed_Harrison_15235",
            "title": "InternalMed_Harrison",
            "content": "other marrow elements. A characteristic feature of zidovudine therapy is an elevated mean corpuscular volume (MCV). Another drug used in patients with HIV infection that has a selective effect on the erythroid series is dapsone. This drug can cause a serious hemolytic anemia in patients who are deficient in glucose-6-phosphate dehydrogenase and can create a functional anemia in others through induction of methemoglobinemia. Folate levels are usually normal in HIV-infected individuals; however, vitamin B12 levels may be depressed as a consequence of achlorhydria or malabsorption. True autoimmune hemolytic anemia is rare, although ~20% of patients with HIV infection may have a positive direct antiglobulin test as a consequence of polyclonal B cell activation. Infection with parvovirus B19 may also cause anemia. It is important to recognize this possibility given the fact that it responds well to treatment with IVIg. Erythropoietin levels in patients with HIV infection and anemia are"
        },
        {
            "id": "InternalMed_Harrison_8437",
            "title": "InternalMed_Harrison",
            "content": "No specific therapy exists for PMF. The causes for anemia are multifarious and include ineffective erythropoiesis uncompensated by splenic extramedullary hematopoiesis, hemodilution due to splenomegaly, splenic sequestration, blood loss secondary to thrombocytopenia or portal hypertension, folic acid deficiency, systemic inflammation, and autoimmune hemolysis. Neither recombinant erythropoietin nor androgens such as danazol have proven to be consistently effective as therapy for anemia. Erythropoietin may worsen splenomegaly and will be ineffective if the serum erythropoietin level is >125 mU/L. Given the inflammatory milieu that characterizes PMF, corticosteroids can ameliorate anemia as well as constitutional symptoms such as fever, chills, night sweats, anorexia, and weight loss, and low-dose thalidomide together with prednisone has proved effective as well. Thrombocytopenia can be due to impaired marrow function, splenic sequestration, or autoimmune destruction"
        },
        {
            "id": "InternalMed_Harrison_8440",
            "title": "InternalMed_Harrison",
            "content": "is attempted. Allopurinol can control significant hyperuricemia, and bone pain can be alleviated by local irradiation. The role of IFN-\u03b1 is still undefined; its side effects are more pronounced in the older individuals, and it may exacerbate the bone marrow failure. The JAK2 inhibitor, ruxolitinib, has proved effective in reducing splenomegaly and alleviating constitutional symptoms in a majority of advanced PMF patients while also prolonging survival, although it does not significantly influence the JAK2 V617F allele burden. Although anemia and thrombocytopenia are its major side effects, these are dose-dependent, and with time, anemia stabilizes and thrombocytopenia may improve. Allogeneic bone marrow transplantation is the only curative treatment for PMF and should be considered in younger patients; nonmyeloablative conditioning regimens may permit hematopoietic cell transplantation to be extended to older individuals, but this approach is currently under investigation."
        },
        {
            "id": "InternalMed_Harrison_8017",
            "title": "InternalMed_Harrison",
            "content": "EPO is particularly useful in anemias in which endogenous EPO levels are inappropriately low, such as CKD or AI. Iron status must be evaluated and iron replaced to obtain optimal effects from EPO. In patients with CKD, the usual dose of EPO is 50\u2013150 U/kg three times a week intravenously. Hemoglobin levels of 10\u201312 g/dL are usually reached within 4\u20136 weeks if iron levels are adequate; 90% of these patients respond. Once a target hemoglobin level is achieved, the EPO dose can be decreased. A decrease in hemoglobin level occurring in the face of EPO therapy usually signifies the development of an infection or iron depletion. Aluminum toxicity and hyperparathyroidism can also compromise the response to EPO. When an infection intervenes, it is best to interrupt the EPO therapy and rely on transfusions to correct the anemia until the infection is adequately treated. The dose of EPO needed to correct chemotherapy-induced anemia in patients with cancer is higher, up to 300 U/kg three times a"
        },
        {
            "id": "InternalMed_Harrison_30706",
            "title": "InternalMed_Harrison",
            "content": "Anemia should be corrected with erythropoietin, administered subcutaneously at doses of 25\u201375 U/kg three times per week. The hematocrit increases after 2\u20136 weeks. A weekly maintenance dose is usually necessary. However, the increased intravascular volume that accompanies the rise in hematocrit can exacerbate supine hypertension."
        },
        {
            "id": "InternalMed_Harrison_8390",
            "title": "InternalMed_Harrison",
            "content": "Immunosuppression, as used in aplastic anemia, also may produce sustained independence from transfusion and improve survival. ATG, cyclosporine, and the anti-CD52 monoclonal antibody alemtuzumab are especially effective in younger MDS patients (<60 years old) with more favorable IPSS scores and who bear the histocompatibility antigen HLA-DR15. HGFs can improve blood counts but, as in most other marrow failure states, have been most beneficial to patients with the least severe pancytopenia. EPO alone or in combination with G-CSF can improve hemoglobin levels, but mainly in those with low serum EPO levels who have no or only a modest need for transfusions. Survival does not appear to be improved by G-CSF treatment alone but may be enhanced by erythropoietin and amelioration of anemia. G-CSF treatment alone failed to improve survival in a controlled trial."
        },
        {
            "id": "Pathology_Robbins_2671",
            "title": "Pathology_Robbins",
            "content": "Withineffectiveerythropoiesis:ironoverload,heartandendocrinefailure Ifsevereandcongenital:growthretardation,bonedeformitiesduetoreactivemarrowhyperplasia ANEMIAOFBLOODLOSS:HEMORRHAGE Anemia of blood loss can be divided into anemia caused by acute bleeding (hemorrhage) and anemia caused by chronic blood loss (described later). The effects of acute bleeding are mainly due to the loss of intravascular volume, which if massive can lead to cardiovascular collapse, shock, and death. If blood loss exceeds 20% of blood volume, the immediate threat is hypovolemic shock rather than anemia. If the patient survives, hemodilution begins at once and achieves its full effect within 2 to 3 days; only then is the full extent of the red cell loss revealed. The anemia is normocytic and normochromic. Recovery from blood loss anemia is enhanced by a compensatory rise in the erythropoietin level, which stimulates increased red cell production and reticulocytosis within a period of 5 to 7 days."
        },
        {
            "id": "Pharmacology_Katzung_3726",
            "title": "Pharmacology_Katzung",
            "content": "Albaramki J et al: Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2012;(1):CD007857. Auerbach M, Al Talib K: Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int 2008;73:528. Barzi A, Sekeres MA: Myelodysplastic syndromes: A practical approach to diagnosis and treatment. Cleve Clin J Med 2010;77:37. Brittenham GM: Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011;364:146. Clark SF: Iron deficiency anemia: diagnosis and management. Curr Opin Gastroenterol 2009;25:122. Darshan D, Fraer DM, Anderson GJ: Molecular basis of iron-loading disorders. Expert Rev Mol Med 2010;12:e36. Gertz MA: Current status of stem cell mobilization. Br J Haematol 2010;150:647. Kessans MR, Gatesman ML, Kockler DR: Plerixafor: A peripheral blood stem cell mobilizer. Pharmacotherapy 2010;30:485."
        },
        {
            "id": "InternalMed_Harrison_4491",
            "title": "InternalMed_Harrison",
            "content": "Therapeutic options for the treatment of anemias have expanded dramatically during the past 30 years. Blood component therapy is available and safe. Recombinant EPO as an adjunct to anemia management has transformed the lives of patients with chronic renal failure on dialysis and reduced transfusion needs of anemic cancer patients receiving chemotherapy. Eventually, patients with inherited disorders of globin synthesis or mutations in the globin gene, such as sickle cell disease, may benefit from the successful introduction of targeted genetic therapy (Chap. 91e)."
        },
        {
            "id": "Pharmacology_Katzung_3618",
            "title": "Pharmacology_Katzung",
            "content": "is common but is not easily treated. It is discussed in the Box: Sickle Cell Disease and Hydroxyurea. Thrombocytopenia and neutropenia are not rare, and some forms are amenable to drug therapy. In this chapter, we first consider treatment of anemia due to deficiency of iron, vitamin B12, or folic acid and then turn to the medical use of hematopoietic growth factors to combat anemia, thrombocytopenia, and neutropenia, and to support stem cell transplantation."
        },
        {
            "id": "InternalMed_Harrison_8015",
            "title": "InternalMed_Harrison",
            "content": "Many patients with hypoproliferative anemias experience recovery of normal hemoglobin levels when the underlying disease is appropriately treated. For those in whom such reversals are not possible\u2014 such as patients with end-stage kidney disease, cancer, and chronic inflammatory diseases\u2014symptomatic anemia requires treatment. The two major forms of treatment are transfusions and EPO."
        },
        {
            "id": "Pediatrics_Nelson_3204",
            "title": "Pediatrics_Nelson",
            "content": "Clinical Manifestations. Patients with Fanconi anemia have numerous characteristic clinical findings (see Table 150-6). Treatment. Hematopoietic stem cell transplantation can cure the pancytopenia caused by bone marrow aplasia. Many patients with Fanconi anemia and about 20% of children with aplastic anemia seem to respond for a time to androgenic therapy, which induces masculinization and may cause liver injury and liver tumors. Androgenic therapy increases RBC synthesis and may diminish transfusion requirements. The effect on granulocytes, and especially the platelet count, is less impressive."
        },
        {
            "id": "Pharmacology_Katzung_3693",
            "title": "Pharmacology_Katzung",
            "content": "TABLE 33\u20134 Clinical uses of hematopoietic growth factors and agents that mimic their actions. levels greater than 11 g/dL. In addition, a meta-analysis of 51 placebo-controlled trials of ESAs in cancer patients reported an increased rate of all-cause mortality and venous thrombosis in those receiving an ESA. Based on the accumulated evidence, it is recommended that the hemoglobin level not exceed 11 g/dL in patients with chronic kidney disease receiving an ESA, and that ESAs be used conservatively in cancer patients (eg, when hemoglobin levels are <10 g/dL) and with the lowest dose needed to avoid transfusion. It is further recommended that ESAs not be used when a cancer therapy is being given with curative intent."
        },
        {
            "id": "Pharmacology_Katzung_3690",
            "title": "Pharmacology_Katzung",
            "content": "The availability of erythropoiesis-stimulating agents (ESAs) has had a significant positive impact for patients with several types of anemia (Table 33\u20134). The ESAs consistently improve the hematocrit and hemoglobin level, often eliminate the need for transfusions, and reliably improve quality of life indices. The ESAs are used routinely in patients with anemia secondary to chronic kidney disease. In patients treated with an ESA, an increase in reticulocyte count is usually observed in about 10 days and an increase in hematocrit and hemoglobin levels in 2\u20136 weeks. Dosages of ESAs are adjusted to maintain a target hemoglobin up to, but not exceeding, 10\u201312 g/dL. To support the increased erythropoiesis, nearly all patients with chronic kidney disease require oral or parenteral iron supplementation. Folate supplementation may also be necessary in some patients."
        },
        {
            "id": "InternalMed_Harrison_6444",
            "title": "InternalMed_Harrison",
            "content": "Anemia associated with chemotherapy can be managed by transfusion of packed RBCs. Transfusion is not undertaken until the hemoglobin falls to <80 g/L (8 g/dL), compromise of end organ function occurs, or an underlying condition (e.g., coronary artery disease) calls for maintenance of hemoglobin >90 g/L (9 g/dL). Patients who are to receive therapy for >2 months on a \u201cstable\u201d regimen and who are likely to require continuing transfusions are also candidates for erythropoietin (EPO). Randomized trials in certain tumors have raised the possibility that EPO use may promote tumor-related adverse events. This information should be considered in the care of individual patients. In the event EPO treatment is undertaken, maintenance of hemoglobin of 90\u2013100 g/L (9\u201310 g/dL) should be the target. In the setting of adequate iron stores and serum EPO levels <100 ng/mL, EPO, 150 U three times a week, can produce a slow increase in hemoglobin over about 2 months of administration. Depot formulations"
        },
        {
            "id": "InternalMed_Harrison_4490",
            "title": "InternalMed_Harrison",
            "content": "and during the treatment of any anemia. Transfusion is discussed in Chap. 138e; iron therapy is discussed in Chap. 126; treatment of megaloblastic anemia is discussed in Chap. 128; treatment of other entities is discussed in their respective chapters (sickle cell anemia, Chap. 127; hemolytic anemias, Chap. 129; aplastic anemia and myelodysplasia, Chap. 130)."
        },
        {
            "id": "InternalMed_Harrison_6445",
            "title": "InternalMed_Harrison",
            "content": "the setting of adequate iron stores and serum EPO levels <100 ng/mL, EPO, 150 U three times a week, can produce a slow increase in hemoglobin over about 2 months of administration. Depot formulations can be administered less frequently. It is unclear whether higher hemoglobin levels, up to 110\u2013120 g/L (11\u201312 g/dL), are associated with improved quality of life to a degree that justifies the more intensive EPO use. Efforts to achieve levels at or above 120 g/L (12 g/dL) have been associated with increased thromboses and mortality rates. EPO may rescue hypoxemic cells from death and contribute to tumor radioresistance."
        },
        {
            "id": "InternalMed_Harrison_4441",
            "title": "InternalMed_Harrison",
            "content": "The critical elements of erythropoiesis\u2014EPO production, iron availability, the proliferative capacity of the bone marrow, and effective maturation of red cell precursors\u2014are used for the initial classification of anemia (see below)."
        },
        {
            "id": "Pathology_Robbins_2668",
            "title": "Pathology_Robbins",
            "content": "pathogenic mechanism. If the onset is slow, the deficit in O2carrying capacity is compensated for by increases in cardiac output, respiratory rate, and red cell 2,3-diphosphoglycerate (DPG), a glycolytic pathway intermediate that enhances the release of O2 from hemoglobin. These adaptive changes mitigate the effects of mild to moderate anemia in otherwise healthy persons but are less effective in those with compromised pulmonary or cardiac function. Pallor, fatigue, and lassitude are common to all forms of anemia. Anemia caused by the premature destruction of red cells (hemolytic anemia) is associated with hyperbilirubinemia, jaundice, and pigment gallstones (if hemolysis is chronic), all related to increases in the turnover of hemoglobin. Anemia that stems from ineffective hematopoiesis (the premature death of marrow erythroid progenitors) is associated with inappropriate increases in iron absorption from the gut, which can lead to iron overload (secondary hemochromatosis) with"
        },
        {
            "id": "Obstentrics_Williams_7697",
            "title": "Obstentrics_Williams",
            "content": "For treatment, adequate iron stores must be ensured. Recombinant eythropoietin has been used successfully to treat anemia stemming from chronic disease (Weiss, 2005). In pregnancies complicated by chronic renal insuiciency, recombinant erythropoietin is usually considered when the hematocrit approximates 20 percent (Cyganek, 2011; Ramin, 2006). One worrisome side efect of this agent is hypertension, which is already prevalent in women with renal disease. Red cell aplasia and antierythropoietin antibodies have also reported (Casadevall, 2002; McCoy, 2008). These anemias are characterized by blood and bone-marrow abnormalities from impaired DNA synthesis. This leads to large cells with arrested nuclear maturation, whereas the cytoplasm matures more normally. Worldwide, the prevalence of megaloblastic anemia during pregnancy varies considerably. It is rare in the United States."
        },
        {
            "id": "InternalMed_Harrison_8887",
            "title": "InternalMed_Harrison",
            "content": "Normocytic and normochromic anemia occurs in ~80% of myeloma patients. It is usually related to the replacement of normal marrow by expanding tumor cells, to the inhibition of hematopoiesis by factors made by the tumor, to reduced production of erythropoietin by the kidney, and to the effects of long-term therapy. In addition, mild hemolysis may contribute to the anemia. A larger than expected fraction of patients may have megaloblastic anemia due to either folate or vitamin B12 deficiency. Granulocytopenia and thrombocytopenia are rare except when therapy-induced. Clotting abnormalities may be seen due to the failure of antibody-coated platelets to function properly; the interaction of the M component with clotting factors I, II, V, VII, or VIII; antibody to clotting factors; or amyloid damage of endothelium. Deep venous thrombosis is also observed with use of thalidomide, lenalidomide, or pomalidomide in combination with dexamethasone. Raynaud\u2019s phenomenon and impaired circulation"
        },
        {
            "id": "Pharmacology_Katzung_3727",
            "title": "Pharmacology_Katzung",
            "content": "Gertz MA: Current status of stem cell mobilization. Br J Haematol 2010;150:647. Kessans MR, Gatesman ML, Kockler DR: Plerixafor: A peripheral blood stem cell mobilizer. Pharmacotherapy 2010;30:485. McKoy JM et al: Epoetin-associated pure red cell aplasia: Past, present, and future considerations. Transfusion 2008;48:1754. Rees DC, Williams TN, Gladwin MT: Sickle-cell disease. Lancet 2010;376:2018. Rizzo JD et al: American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28:4996. Sauer J, Mason JB, Choi SW: Too much folate: A risk factor for cancer and cardiovascular disease? Curr Opin Clin Nutr Metab Care 2009;12:30. Solomon LR: Disorders of cobalamin (vitamin B12) metabolism: Emerging concepts in pathophysiology, diagnosis and treatment. Blood Rev 2007;21:113. Stasi R et al: Thrombopoietic agents. Blood Rev 2010;24:179."
        },
        {
            "id": "InternalMed_Harrison_8018",
            "title": "InternalMed_Harrison",
            "content": "to correct the anemia until the infection is adequately treated. The dose of EPO needed to correct chemotherapy-induced anemia in patients with cancer is higher, up to 300 U/kg three times a week, and only approximately 60% of patients respond. Because of evidence that there is an increased risk of thromboembolic complications and tumor progression with EPO administration, the risks and benefits of using EPO in such patients must be weighed carefully, and the target hemoglobin should be that necessary to avoid transfusions."
        },
        {
            "id": "Pathology_Robbins_2667",
            "title": "Pathology_Robbins",
            "content": "As discussed later, the clinical consequences of anemia are determined by its severity, rapidity of onset, and underlying http://ebooksmedicine.net Table 12.2 Adult Reference Ranges for Red Blood Cells Hemoglobin(Hb)g/dL13.2\u201316.711.9\u201315.0 11.5\u201314.8 aReferencerangesvaryamonglaboratories.Thereferencerangesforthelaboratoryprovidingtheresultshouldalwaysbeusedininterpretingalaboratorytest."
        },
        {
            "id": "Pathology_Robbins_2752",
            "title": "Pathology_Robbins",
            "content": "Clinical Features. As in anemia of iron deficiency, the serum iron levels usually are low in the anemia of chronic disease, and the red cells may be slightly hypochromic and microcytic. Unlike iron deficiency anemia, however, storage iron in the bone marrow and serum ferritin are increased and the total iron-binding capacity is reduced. Administration of erythropoietin and iron can improve the anemia, but only effective treatment of the underlying condition is curative. The two principal causes of megaloblastic anemia are folate deficiency and vitamin B12 deficiency. Both vitamins are required for DNA synthesis and the effects of their deficiency on hematopoiesis are essentially identical. However, the causes and consequences of folate and vitamin B12 deficiency differ in important ways. We will first review some of the common features and then touch on those that are specific to folate and vitamin B12 deficiency."
        },
        {
            "id": "InternalMed_Harrison_8063",
            "title": "InternalMed_Harrison",
            "content": "three crises per year requiring hospitalization. The utility of this agent for reducing the incidence of other complications (priapism, retinopathy) is under evaluation, as are the long-term side effects. To date, however, minimal risk of bone marrow dyscrasias or other neoplasms has been documented. Hydroxyurea offers broad benefits to most patients whose disease is severe enough to impair their functional status, and it may improve survival. HbF levels increase in most patients within a few months. The antitumor drug 5-azacytidine was the first agent found to elevate HbF. It never achieved widespread use because of concerns about acute toxicity and carcinogenesis. However, low doses of the related agent 5-deoxyazacytidine (decitabine) can elevate HbF with more acceptable toxicity. Bone marrow transplantation can provide definitive cures but is known to be effective and safe only in children. Clinical trials studying partially myeloablative conditioning regimens (\u201cmini\u201d transplants)"
        },
        {
            "id": "InternalMed_Harrison_18294",
            "title": "InternalMed_Harrison",
            "content": "Anemia is common in heart failure patients, reduces functional status and quality of life, and is associated with increased proclivity for hospital admissions and mortality. Anemia in heart failure is more common in the elderly, in those with advanced stages of HFrEF, in the presence of renal insufficiency, and in women and African Americans. The mechanisms include iron deficiency, dysregulation of iron metabolism, and occult gastrointestinal bleeding. Intravenous iron using either iron sucrose or carboxymaltose (Ferric Carboxymaltose Assessment in Patients with Iron Deficiency and Chronic Heart Failure [FAIR-HF] trial) has been shown to correct anemia and improve functional capacity. Erythropoiesis-regulating agents such as erythropoietin analogues have been studied with disappointing results. The Reduction of Events by Darbepoetin Alfa in Heart Failure (RED-HF) trial evaluated 2278 mild-to-moderate anemia patients with HFrEF and demonstrated that treatment with darbepoetin alfa did"
        },
        {
            "id": "Pediatrics_Nelson_3186",
            "title": "Pediatrics_Nelson",
            "content": "\u2021Usually normochromic; 25% of cases are microcytic. \u00a7Red blood cell distribution width quantitates the degree of anisocytosis (different sizes) of red blood cells. of elemental iron induces an increase in hemoglobin of 0.25 to 0.4 g/dL/day (a 1%/day increase in hematocrit). If the hemoglobin level fails to increase within 2 weeks after institution of iron treatment, careful re-evaluation for ongoing blood loss, development of infection, poor compliance, or other causes of microcytic anemia is required (Table 150-4; see Fig. 150-1)."
        },
        {
            "id": "InternalMed_Harrison_9047",
            "title": "InternalMed_Harrison",
            "content": "Granulocyte and granulocyte-macrophage colony-stimulating factors are clinically useful to hasten leukocyte recovery in patients with leukopenia related to high-dose chemotherapy. Erythropoietin stimulates erythrocyte production in patients with anemia of chronic renal failure and other conditions, thus avoiding or reducing the need for transfusion. This hormone can also stimulate erythropoiesis in the autologous donor to enable additional donation."
        },
        {
            "id": "InternalMed_Harrison_23806",
            "title": "InternalMed_Harrison",
            "content": "Side effects of IFN therapy are described above in the section on treatment of chronic hepatitis B. The most pronounced side effect of ribavirin therapy is hemolysis; a reduction in hemoglobin of up to 2\u22123 g or in hematocrit of 5\u221210% can be anticipated. A small, unpredictable proportion of patients experience profound, brisk hemolysis, resulting in symptomatic anemia; therefore, close monitoring of blood counts is crucial, and ribavirin should be avoided in patients with anemia or hemoglobinopathies and in patients with coronary artery disease or cerebrovascular disease, in whom anemia can precipitate an ischemic event. When symptomatic anemia occurs, ribavirin dose reductions or addition of erythropoietin to boost red blood cell levels may be required; erythropoietin has been shown to improve patients\u2019 quality of life but not the likelihood of achieving an SVR. If ribavirin is stopped during therapy, SVR rates fall, but responsiveness can be maintained as long as ribavirin is not"
        },
        {
            "id": "InternalMed_Harrison_9098",
            "title": "InternalMed_Harrison",
            "content": "Transplantation from matched siblings after a preparative regimen of high-dose cyclophosphamide and antithymocyte globulin can cure up to 90% of patients age <40 years with severe aplastic anemia. Results in older patients and in recipients of mismatched family member or unrelated marrow are less favorable; therefore, a trial of immunosuppressive therapy is generally recommended for such patients before considering transplantation. Transplantation is effective in all forms of aplastic anemia including, for example, the syndromes associated with paroxysmal nocturnal hemoglobinuria and Fanconi\u2019s anemia. Patients with Fanconi\u2019s anemia are abnormally sensitive to the toxic effects of alkylating agents, and so less intensive preparative regimens must be used in their treatment (Chap. 130). Marrow transplantation from an HLA-identical sibling following a preparative regimen of busulfan and cyclophosphamide can cure 80\u201390% of patients with thalassemia major. The best outcomes can"
        }
    ],
    "scores": [
        0.028203610876727223,
        0.026720607755090515,
        0.023947446404247317,
        0.02302100806773704,
        0.022767106898134278,
        0.021784868102198728,
        0.021738382820420038,
        0.019424799622819428,
        0.019417475728155338,
        0.01916024935826916,
        0.018874643874643875,
        0.01837336704593342,
        0.01805465191932336,
        0.017946241751166908,
        0.01786843769765971,
        0.017704661182922053,
        0.017489400363416112,
        0.017182890855457225,
        0.016935937625592798,
        0.016560678325384208,
        0.01628707627118644,
        0.016234616391725583,
        0.01618059633326809,
        0.016095669036845506,
        0.015998551074619657,
        0.015806298839687427,
        0.015752765752765754,
        0.015669856459330143,
        0.015564437984496124,
        0.015512265512265512,
        0.015511833475905333,
        0.015362511052166225
    ]
}